Immunoadsorption as treatment option in dilated cardiomyopathy

Area of Science:

• Immunology
• Cardiology
• Pathophysiology

Background:

• Dilated cardiomyopathy (DCM) is associated with immune system abnormalities.
• Cardiac autoantibodies are frequently found in DCM patients.
• These autoantibodies may contribute to cardiac dysfunction.

Purpose of the Study:

• To investigate the role of circulating cardiac autoantibodies in DCM.
• To evaluate the efficacy of immunoadsorption (IA) in removing these antibodies.
• To assess the impact of IA on cardiac function and myocardial inflammation in DCM.

Main Methods:

• Utilizing immunoadsorption (IA) to extract circulating antibodies from DCM patients.
• Conducting open controlled pilot studies to assess treatment outcomes.
• Analyzing changes in cardiac function and myocardial inflammation post-IA.
• Investigating the predictive value of cardiodepressive antibodies for hemodynamic benefits.

Main Results:

• IA effectively removes circulating cardiac autoantibodies.
• IA treatment leads to significant improvement in cardiac function in DCM patients.
• IA reduces myocardial inflammation.
• The presence of cardiodepressive antibodies predicts positive hemodynamic responses to IA.
• Cardiodepressive antibodies are identified as immunoglobulin G subclass 3.

Conclusions:

• Removal of cardiodepressive antibodies via IA is a potential therapeutic strategy for DCM.
• IA offers a promising approach to improve cardiac function and reduce inflammation in DCM.
• Targeting specific autoantibodies, like immunoglobulin G subclass 3, may be key to treating DCM effectively.